Our findings suggest that combination of MRA, SGLT2i, and GLP-1 RA were the most effective for all clinical HF event (P-score 1.00), followed by the double combinations of MRA and GLP-1 RA strategies for HF hospitalization (P-score 0.77) and cardiovascular death (P-score 0.75), and SGLT2 and GLP-1 RA strategies for the composite endpoint (P-score 0.77). The gene discussed is SLC5A2; the disease is hydrops fetalis.